speb/financial-data huggingface dataset:
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 2551000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Interest Expense: 80056000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 23378000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 80056000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 23378000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -41083000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 31335000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Inventory: 1305584000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 1305584000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 5210783000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 5210783000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 615361000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Investment Properties: 6656167000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Investment Properties: 6656167000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 750000000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 823666000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 823666000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 823666000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 823666000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -60000000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Net Debt: 623311000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 623311000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income: -17238000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -17238000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -17238000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -17238000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -17238000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: -135752000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -17238000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Interest Income: -80056000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -23378000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Investment Properties Purchase And Sale: -4379000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 581533000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -60000000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -60000000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -80056000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -23378000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 6872000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Net PPE: 58000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 58000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: 0.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Net Preferred Stock Issuance: 750000000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 1517702000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 1517702000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 147976000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 147976000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: -54293000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -17066000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Normalized Income: -112201000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Normalized Income: -17238000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: -1514317000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Operating Income: -96261000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Operating Income: -23764000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Operating Revenue: 9924000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 2551000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 285000000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 285000000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 140568000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 140568000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 434000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 434000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 1487117000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 1487117000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -5315000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 40565000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 6353000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 100430000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 25022000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Other Properties: 58000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 58000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 301737000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 301737000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Payables: 12069000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Payables: 12069000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Preferred Stock Issuance: 750000000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Pretax Income: -135752000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Pretax Income: -40789000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 49849000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 0.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 0.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 1403000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 345000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -60000000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 581533000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Share Issued: 285000000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 285000000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 4337117000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 4337117000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 1517702000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1517702000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Tax Provision: -23551000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Tax Provision: -23551000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.17
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 5041000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 5041000.00
HEMIPROP.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: 933000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Assets: 11628453000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 11628453000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 5160783000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 5160783000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Debt: 873666000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 873666000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 4337117000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 4337117000.00
HEMIPROP.NS income_statement (annual, 2026-03-31) — Total Expenses: 106185000.00
HEMIPROP.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 26315000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 7291336000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 7291336000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 9623616000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 9623616000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 823666000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 823666000.00
HEMIPROP.NS balance_sheet (annual, 2026-03-31) — Working Capital: -4462833000.00
HEMIPROP.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: -4462833000.00
HEMO.L balance_sheet (annual, 2021-12-31) — Current Debt: 0.00
HEMO.L cash_flow (annual, 2021-12-31) — Issuance Of Debt: 12000000.00
HEMO.L cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 12000000.00
HEMO.L cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -3183281.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Intangibles Purchase And Sale: -181743.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: -138913.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: 8816719.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: 8816719.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Other Investing Changes: -138913.00
HEMO.L cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: 8816719.00
HEMO.L balance_sheet (annual, 2021-12-31) — Non Current Deferred Assets: 0.00
HEMO.L income_statement (annual, 2021-12-31) — Other Special Charges: -171875.00
HEMO.L cash_flow (annual, 2021-12-31) — Purchase Of Intangibles: -181743.00
HEMO.L cash_flow (annual, 2021-12-31) — Purchase Of Investment: -138913.00
HEMO.L cash_flow (annual, 2021-12-31) — Repayment Of Debt: -3183281.00
HEMO.L cash_flow (annual, 2021-12-31) — Short Term Debt Issuance: 12000000.00
HEMO.L cash_flow (annual, 2021-12-31) — Short Term Debt Payments: -3183281.00
HEMO.L income_statement (annual, 2021-12-31) — Special Income Charges: 171875.00
HEMO.L income_statement (annual, 2021-12-31) — Total Unusual Items: 171875.00
HEMO.L income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: 171875.00
HEMO.L income_statement (annual, 2022-12-31) — +Operating Expense: 3333665.00
HEMO.L income_statement (annual, 2022-12-31) — +Total Revenue: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Accounts Payable: 374342.00
HEMO.L balance_sheet (annual, 2022-12-31) — Accounts Receivable: 146.00
HEMO.L balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -604286.00
HEMO.L balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 16808647.00
HEMO.L income_statement (annual, 2022-12-31) — Basic Average Shares: 2449373.00
HEMO.L income_statement (annual, 2022-12-31) — Basic EPS: -2.00
HEMO.L cash_flow (annual, 2022-12-31) — Beginning Cash Position: 6840969.00
HEMO.L balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 722171.00
HEMO.L cash_flow (annual, 2022-12-31) — Capital Expenditure: -428945.00
HEMO.L balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 3422835.00
HEMO.L balance_sheet (annual, 2022-12-31) — Capital Stock: 9797493.00
HEMO.L balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 2532758.00
HEMO.L balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 2532758.00
HEMO.L cash_flow (annual, 2022-12-31) — Change In Payable: -27120.00
HEMO.L cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 271819.00
HEMO.L cash_flow (annual, 2022-12-31) — Change In Receivables: -2109.00
HEMO.L cash_flow (annual, 2022-12-31) — Change In Working Capital: 242590.00
HEMO.L cash_flow (annual, 2022-12-31) — Changes In Cash: -3441002.00
HEMO.L balance_sheet (annual, 2022-12-31) — Common Stock: 9797493.00
HEMO.L balance_sheet (annual, 2022-12-31) — Common Stock Equity: 3275428.00
HEMO.L cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
HEMO.L income_statement (annual, 2022-12-31) — Cost Of Revenue: 2196822.00
HEMO.L balance_sheet (annual, 2022-12-31) — Current Assets: 2594782.00
HEMO.L balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 322157.00
HEMO.L balance_sheet (annual, 2022-12-31) — Current Debt: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 322157.00
HEMO.L balance_sheet (annual, 2022-12-31) — Current Liabilities: 748411.00
HEMO.L cash_flow (annual, 2022-12-31) — Depreciation: 195246.00
HEMO.L cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 195246.00
HEMO.L income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 564072.00
HEMO.L income_statement (annual, 2022-12-31) — Depreciation Income Statement: 564072.00
HEMO.L income_statement (annual, 2022-12-31) — Diluted Average Shares: 2449373.00
HEMO.L income_statement (annual, 2022-12-31) — Diluted EPS: -2.00
HEMO.L income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -3979314.00
HEMO.L income_statement (annual, 2022-12-31) — EBIT: -3986949.00
HEMO.L income_statement (annual, 2022-12-31) — EBITDA: -3422877.00
HEMO.L cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -876209.00
HEMO.L cash_flow (annual, 2022-12-31) — End Cash Position: 2532758.00
HEMO.L cash_flow (annual, 2022-12-31) — Financing Cash Flow: -110144.00
HEMO.L cash_flow (annual, 2022-12-31) — Free Cash Flow: -3339549.00
HEMO.L income_statement (annual, 2022-12-31) — General And Administrative Expense: 1345292.00
HEMO.L balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 441493.00
HEMO.L balance_sheet (annual, 2022-12-31) — Gross PPE: 4519799.00
HEMO.L income_statement (annual, 2022-12-31) — Gross Profit: -2196822.00
HEMO.L income_statement (annual, 2022-12-31) — Interest Expense: 33.00
HEMO.L income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 33.00
HEMO.L income_statement (annual, 2022-12-31) — Interest Income: 10599.00
HEMO.L income_statement (annual, 2022-12-31) — Interest Income Non Operating: 10599.00
HEMO.L cash_flow (annual, 2022-12-31) — Interest Received Cfi: 10599.00
HEMO.L balance_sheet (annual, 2022-12-31) — Invested Capital: 3275428.00
HEMO.L cash_flow (annual, 2022-12-31) — Investing Cash Flow: -420254.00
HEMO.L cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 3100678.00
HEMO.L balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 3100678.00
HEMO.L balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 32954.00
HEMO.L balance_sheet (annual, 2022-12-31) — Minority Interest: -31908.00
HEMO.L income_statement (annual, 2022-12-31) — Minority Interests: 7668.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 12937.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income: -3979314.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -3979314.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -3986982.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -3979314.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -3979314.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -3986982.00
HEMO.L income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -3986982.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: 0.00
HEMO.L income_statement (annual, 2022-12-31) — Net Interest Income: 10566.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -1908.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 0.00
HEMO.L income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 10566.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Other Investing Changes: -1908.00
HEMO.L balance_sheet (annual, 2022-12-31) — Net PPE: 3915513.00
HEMO.L cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -428945.00
HEMO.L cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 2833935.00
HEMO.L balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 140821.00
HEMO.L income_statement (annual, 2022-12-31) — Normalized EBITDA: -3422877.00
HEMO.L income_statement (annual, 2022-12-31) — Normalized Income: -3979314.00
HEMO.L cash_flow (annual, 2022-12-31) — Operating Cash Flow: -2910604.00
HEMO.L income_statement (annual, 2022-12-31) — Operating Income: -5530487.00
HEMO.L income_statement (annual, 2022-12-31) — Operating Revenue: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 2449373.00
HEMO.L cash_flow (annual, 2022-12-31) — Other Cash Adjustment Outside Changein Cash: 9000.00
HEMO.L balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 441493.00
HEMO.L cash_flow (annual, 2022-12-31) — Other Non Cash Items: 617030.00
HEMO.L balance_sheet (annual, 2022-12-31) — Other Properties: 3764674.00
HEMO.L income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Payables: 374342.00
HEMO.L balance_sheet (annual, 2022-12-31) — Prepaid Assets: 52214.00
HEMO.L income_statement (annual, 2022-12-31) — Pretax Income: -3986982.00
HEMO.L balance_sheet (annual, 2022-12-31) — Properties: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Purchase Of Investment: -1908.00
HEMO.L cash_flow (annual, 2022-12-31) — Purchase Of PPE: -428945.00
HEMO.L income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 2196822.00
HEMO.L income_statement (annual, 2022-12-31) — Reconciled Depreciation: 195246.00
HEMO.L cash_flow (annual, 2022-12-31) — Repayment Of Debt: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Retained Earnings: -17114056.00
HEMO.L income_statement (annual, 2022-12-31) — Selling General And Administration: 1345292.00
HEMO.L balance_sheet (annual, 2022-12-31) — Share Issued: 2449373.00
HEMO.L cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Short Term Debt Payments: 0.00
HEMO.L cash_flow (annual, 2022-12-31) — Stock Based Compensation: 17575.00
HEMO.L balance_sheet (annual, 2022-12-31) — Stockholders Equity: 3275428.00
HEMO.L balance_sheet (annual, 2022-12-31) — Tangible Book Value: 2833935.00
HEMO.L income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
HEMO.L income_statement (annual, 2022-12-31) — Tax Provision: 0.00
HEMO.L income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
HEMO.L balance_sheet (annual, 2022-12-31) — Taxes Receivable: 9664.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Assets: 7092609.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Capitalization: 3275428.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Debt: 3422835.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 3243520.00
HEMO.L income_statement (annual, 2022-12-31) — Total Expenses: 5530487.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 3849089.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 4497827.00
HEMO.L balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 3100678.00
HEMO.L income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -3997548.00
HEMO.L balance_sheet (annual, 2022-12-31) — Working Capital: 1846371.00
HEMO.L income_statement (annual, 2023-12-31) — +Operating Expense: 3866345.00
HEMO.L income_statement (annual, 2023-12-31) — +Total Revenue: 0.00
HEMO.L balance_sheet (annual, 2023-12-31) — Accounts Payable: 301707.00
HEMO.L balance_sheet (annual, 2023-12-31) — Accounts Receivable: 1074.00
HEMO.L balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -700647.00
HEMO.L balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 19938556.00
HEMO.L income_statement (annual, 2023-12-31) — Basic Average Shares: 2822841.00
HEMO.L income_statement (annual, 2023-12-31) — Basic EPS: -2.37
HEMO.L cash_flow (annual, 2023-12-31) — Beginning Cash Position: 2532758.00
HEMO.L balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 687653.00
HEMO.L cash_flow (annual, 2023-12-31) — Capital Expenditure: -117285.00
HEMO.L balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 2945886.00
HEMO.L balance_sheet (annual, 2023-12-31) — Capital Stock: 11755660.00
HEMO.L balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 1247601.00
HEMO.L balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 1247601.00
HEMO.L cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 306759.00
HEMO.L cash_flow (annual, 2023-12-31) — Change In Payable: 28579.00
HEMO.L cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -866644.00
HEMO.L cash_flow (annual, 2023-12-31) — Change In Receivables: 4469.00
HEMO.L cash_flow (annual, 2023-12-31) — Change In Working Capital: -526837.00
HEMO.L cash_flow (annual, 2023-12-31) — Changes In Cash: -1688200.00
HEMO.L balance_sheet (annual, 2023-12-31) — Common Stock: 11755660.00
HEMO.L balance_sheet (annual, 2023-12-31) — Common Stock Equity: 2818729.00
HEMO.L cash_flow (annual, 2023-12-31) — Common Stock Issuance: 5088076.00
HEMO.L income_statement (annual, 2023-12-31) — Cost Of Revenue: 1692203.00
HEMO.L balance_sheet (annual, 2023-12-31) — Current Assets: 2169614.00
HEMO.L balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 362522.00
HEMO.L balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 362522.00
HEMO.L balance_sheet (annual, 2023-12-31) — Current Liabilities: 741523.00
HEMO.L cash_flow (annual, 2023-12-31) — Depreciation: 645681.00
HEMO.L cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 645681.00
HEMO.L income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 645681.00
HEMO.L income_statement (annual, 2023-12-31) — Depreciation Income Statement: 645681.00
HEMO.L income_statement (annual, 2023-12-31) — Diluted Average Shares: 2822841.00
HEMO.L income_statement (annual, 2023-12-31) — Diluted EPS: -2.37
HEMO.L income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -6690678.00
HEMO.L income_statement (annual, 2023-12-31) — EBIT: -6380502.00
HEMO.L income_statement (annual, 2023-12-31) — EBITDA: -5734821.00
HEMO.L cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 403043.00
HEMO.L cash_flow (annual, 2023-12-31) — End Cash Position: 1247601.00
HEMO.L cash_flow (annual, 2023-12-31) — Financing Cash Flow: 4449311.00
HEMO.L cash_flow (annual, 2023-12-31) — Free Cash Flow: -6222855.00
HEMO.L income_statement (annual, 2023-12-31) — General And Administrative Expense: 1069619.00
HEMO.L balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 470173.00
HEMO.L balance_sheet (annual, 2023-12-31) — Gross PPE: 4013085.00
HEMO.L income_statement (annual, 2023-12-31) — Gross Profit: -1692203.00
HEMO.L income_statement (annual, 2023-12-31) — Interest Expense: 315991.00
HEMO.L income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 315991.00
HEMO.L income_statement (annual, 2023-12-31) — Interest Income: 85344.00
HEMO.L income_statement (annual, 2023-12-31) — Interest Income Non Operating: 85344.00
HEMO.L cash_flow (annual, 2023-12-31) — Interest Received Cfi: 85344.00
HEMO.L balance_sheet (annual, 2023-12-31) — Invested Capital: 2818729.00
HEMO.L cash_flow (annual, 2023-12-31) — Investing Cash Flow: -31941.00
HEMO.L cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 5088076.00
HEMO.L balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 2583364.00
HEMO.L balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 2583364.00
HEMO.L balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 44480.00
HEMO.L balance_sheet (annual, 2023-12-31) — Minority Interest: -37723.00
HEMO.L income_statement (annual, 2023-12-31) — Minority Interests: 5815.00
HEMO.L cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 5088076.00
HEMO.L cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: -1485.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income: -6690678.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -6690678.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -6696493.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -6690678.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -6690678.00
HEMO.L cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -6696493.00
HEMO.L income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -6696493.00
HEMO.L income_statement (annual, 2023-12-31) — Net Interest Income: -230647.00
HEMO.L cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 0.00
HEMO.L income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -230647.00
HEMO.L balance_sheet (annual, 2023-12-31) — Net PPE: 3312438.00
HEMO.L cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -117285.00
HEMO.L balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 2348556.00
HEMO.L balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 153668.00
HEMO.L income_statement (annual, 2023-12-31) — Normalized EBITDA: -5734821.00
HEMO.L income_statement (annual, 2023-12-31) — Normalized Income: -6690678.00
HEMO.L cash_flow (annual, 2023-12-31) — Operating Cash Flow: -6105570.00
HEMO.L income_statement (annual, 2023-12-31) — Operating Income: -5558548.00
HEMO.L income_statement (annual, 2023-12-31) — Operating Revenue: 0.00
HEMO.L balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 2938914.00
HEMO.L balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 470173.00
HEMO.L cash_flow (annual, 2023-12-31) — Other Non Cash Items: 230728.00
HEMO.L balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 28680.00
HEMO.L balance_sheet (annual, 2023-12-31) — Other Properties: 3280952.00
HEMO.L income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
HEMO.L balance_sheet (annual, 2023-12-31) — Payables: 301707.00
HEMO.L balance_sheet (annual, 2023-12-31) — Prepaid Assets: 916875.00
HEMO.L income_statement (annual, 2023-12-31) — Pretax Income: -6696493.00
HEMO.L balance_sheet (annual, 2023-12-31) — Properties: 0.00
HEMO.L cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
HEMO.L cash_flow (annual, 2023-12-31) — Purchase Of PPE: -117285.00
HEMO.L income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 1692203.00
HEMO.L income_statement (annual, 2023-12-31) — Reconciled Depreciation: 645681.00
HEMO.L balance_sheet (annual, 2023-12-31) — Retained Earnings: -23804734.00
HEMO.L income_statement (annual, 2023-12-31) — Selling General And Administration: 1069619.00
HEMO.L balance_sheet (annual, 2023-12-31) — Share Issued: 2938914.00
HEMO.L cash_flow (annual, 2023-12-31) — Stock Based Compensation: 242836.00
HEMO.L balance_sheet (annual, 2023-12-31) — Stockholders Equity: 2818729.00
HEMO.L balance_sheet (annual, 2023-12-31) — Tangible Book Value: 2348556.00
HEMO.L income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
HEMO.L income_statement (annual, 2023-12-31) — Tax Provision: 0.00
HEMO.L income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
HEMO.L balance_sheet (annual, 2023-12-31) — Taxes Receivable: 4064.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Assets: 6105893.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Capitalization: 2818729.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Debt: 2945886.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 2781006.00
HEMO.L income_statement (annual, 2023-12-31) — Total Expenses: 5558548.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 3324887.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 3936279.00
HEMO.L balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 2583364.00
HEMO.L income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -6465846.00
HEMO.L balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 0.00
HEMO.L balance_sheet (annual, 2023-12-31) — Working Capital: 1428091.00
HEMO.L income_statement (annual, 2024-12-31) — +Operating Expense: 4425002.00
HEMO.L income_statement (annual, 2024-12-31) — +Total Revenue: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Accounts Payable: 683284.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Accounts Payable: 683284.00
HEMO.L balance_sheet (annual, 2024-12-31) — Accounts Receivable: 3768.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 3768.00
HEMO.L balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -946862.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -946862.00
HEMO.L balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 21388546.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Additional Paid In Capital: 21388546.00
HEMO.L income_statement (annual, 2024-12-31) — Basic Average Shares: 3301431.00
HEMO.L income_statement (annual, 2024-12-31) — Basic EPS: -1.81
HEMO.L cash_flow (annual, 2024-12-31) — Beginning Cash Position: 1247601.00
HEMO.L balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 698227.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 698227.00
HEMO.L cash_flow (annual, 2024-12-31) — Capital Expenditure: -13285.00
HEMO.L balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 2623086.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 2623086.00
HEMO.L balance_sheet (annual, 2024-12-31) — Capital Stock: 35045.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Capital Stock: 35045.00
HEMO.L balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 159265.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 159265.00
HEMO.L balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 159265.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 159265.00
HEMO.L cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 277284.00
HEMO.L cash_flow (annual, 2024-12-31) — Change In Payable: 346521.00
HEMO.L cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 258880.00
HEMO.L cash_flow (annual, 2024-12-31) — Change In Receivables: -2637.00
HEMO.L cash_flow (annual, 2024-12-31) — Change In Working Capital: 880048.00
HEMO.L cash_flow (annual, 2024-12-31) — Changes In Cash: -1064338.00
HEMO.L balance_sheet (annual, 2024-12-31) — Common Stock: 35045.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Common Stock: 35045.00
HEMO.L balance_sheet (annual, 2024-12-31) — Common Stock Equity: 897514.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 897514.00
HEMO.L cash_flow (annual, 2024-12-31) — Common Stock Issuance: 3712490.00
HEMO.L income_statement (annual, 2024-12-31) — Cost Of Revenue: 1301692.00
HEMO.L balance_sheet (annual, 2024-12-31) — Current Assets: 839048.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Current Assets: 839048.00
HEMO.L balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 423673.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 423673.00
HEMO.L balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 423673.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 423673.00
HEMO.L balance_sheet (annual, 2024-12-31) — Current Liabilities: 1158653.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 1158653.00
HEMO.L cash_flow (annual, 2024-12-31) — Depreciation: 639285.00
HEMO.L cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 639285.00
HEMO.L income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 639285.00
HEMO.L income_statement (annual, 2024-12-31) — Depreciation Income Statement: 639285.00
HEMO.L income_statement (annual, 2024-12-31) — Diluted Average Shares: 3301431.00
HEMO.L income_statement (annual, 2024-12-31) — Diluted EPS: -1.81
HEMO.L income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -5619181.00
HEMO.L income_statement (annual, 2024-12-31) — EBIT: -5353923.00
HEMO.L income_statement (annual, 2024-12-31) — EBITDA: -4714638.00
HEMO.L cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -23998.00
HEMO.L cash_flow (annual, 2024-12-31) — End Cash Position: 159265.00
HEMO.L cash_flow (annual, 2024-12-31) — Financing Cash Flow: 3077453.00
HEMO.L cash_flow (annual, 2024-12-31) — Free Cash Flow: -4153344.00
HEMO.L cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
HEMO.L cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 0.00
HEMO.L income_statement (annual, 2024-12-31) — General And Administrative Expense: 1526293.00
HEMO.L balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 477403.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Goodwill And Other Intangible Assets: 477403.00
HEMO.L balance_sheet (annual, 2024-12-31) — Gross PPE: 3674083.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Gross PPE: 3674083.00
HEMO.L income_statement (annual, 2024-12-31) — Gross Profit: -1301692.00
HEMO.L income_statement (annual, 2024-12-31) — Interest Expense: 271555.00
HEMO.L income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 271555.00
HEMO.L income_statement (annual, 2024-12-31) — Interest Income: 23164.00
HEMO.L income_statement (annual, 2024-12-31) — Interest Income Non Operating: 23164.00
HEMO.L cash_flow (annual, 2024-12-31) — Interest Received Cfi: 23164.00
HEMO.L balance_sheet (annual, 2024-12-31) — Invested Capital: 897514.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Invested Capital: 897514.00
HEMO.L cash_flow (annual, 2024-12-31) — Investing Cash Flow: -1732.00
HEMO.L cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 3712490.00
HEMO.L balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 2199413.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 2199413.00
HEMO.L balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 2199413.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 2199413.00
HEMO.L balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 45164.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 45164.00
HEMO.L balance_sheet (annual, 2024-12-31) — Minority Interest: -44020.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Minority Interest: -44020.00
HEMO.L income_statement (annual, 2024-12-31) — Minority Interests: 6297.00
HEMO.L cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 3712490.00
HEMO.L cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: -626240.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income: -5619181.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -5619181.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -5625478.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -5619181.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -5619181.00
HEMO.L cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -5625478.00
HEMO.L income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -5625478.00
HEMO.L income_statement (annual, 2024-12-31) — Net Interest Income: -248391.00
HEMO.L income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -248391.00
HEMO.L cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -11611.00
HEMO.L balance_sheet (annual, 2024-12-31) — Net PPE: 2727221.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Net PPE: 2727221.00
HEMO.L cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -13285.00
HEMO.L balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 420111.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 420111.00
HEMO.L balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 167888.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Non Current Prepaid Assets: 167888.00
HEMO.L income_statement (annual, 2024-12-31) — Normalized EBITDA: -4714638.00
HEMO.L income_statement (annual, 2024-12-31) — Normalized Income: -5619181.00
HEMO.L cash_flow (annual, 2024-12-31) — Operating Cash Flow: -4140059.00
HEMO.L income_statement (annual, 2024-12-31) — Operating Income: -5726694.00
HEMO.L income_statement (annual, 2024-12-31) — Operating Revenue: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 3504539.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 3504539.00
HEMO.L balance_sheet (annual, 2024-12-31) — Other Equity Interest: 13983115.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: 13983115.00
HEMO.L balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 477403.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Other Intangible Assets: 477403.00
HEMO.L cash_flow (annual, 2024-12-31) — Other Non Cash Items: 248391.00
HEMO.L balance_sheet (annual, 2024-12-31) — Other Properties: 2930692.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Other Properties: 2930692.00
HEMO.L income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Payables: 683284.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Payables: 683284.00
HEMO.L balance_sheet (annual, 2024-12-31) — Prepaid Assets: 671926.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 671926.00
HEMO.L income_statement (annual, 2024-12-31) — Pretax Income: -5625478.00
HEMO.L balance_sheet (annual, 2024-12-31) — Properties: 0.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
HEMO.L cash_flow (annual, 2024-12-31) — Purchase Of PPE: -13285.00
HEMO.L income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 1301692.00
HEMO.L income_statement (annual, 2024-12-31) — Reconciled Depreciation: 639285.00
HEMO.L balance_sheet (annual, 2024-12-31) — Retained Earnings: -29423915.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -29423915.00
HEMO.L income_statement (annual, 2024-12-31) — Selling General And Administration: 1526293.00
HEMO.L balance_sheet (annual, 2024-12-31) — Share Issued: 3504539.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Share Issued: 3504539.00
HEMO.L income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
HEMO.L cash_flow (annual, 2024-12-31) — Stock Based Compensation: 343935.00
HEMO.L balance_sheet (annual, 2024-12-31) — Stockholders Equity: 897514.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 897514.00
HEMO.L balance_sheet (annual, 2024-12-31) — Tangible Book Value: 420111.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 420111.00
HEMO.L income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
HEMO.L income_statement (annual, 2024-12-31) — Tax Provision: 0.00
HEMO.L income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Taxes Receivable: 4089.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 4089.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Assets: 4211560.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Assets: 4211560.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Capitalization: 897514.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 897514.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Debt: 2623086.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Debt: 2623086.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 853494.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 853494.00
HEMO.L income_statement (annual, 2024-12-31) — Total Expenses: 5726694.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 3358066.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 3358066.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 3372512.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 3372512.00
HEMO.L balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2199413.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2199413.00
HEMO.L income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -5377087.00
HEMO.L income_statement (annual, 2024-12-31) — Total Unusual Items: 0.00
HEMO.L income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 0.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Treasury Shares Number: 0.00
HEMO.L balance_sheet (annual, 2024-12-31) — Working Capital: -319605.00
HEMO.L balance_sheet (quarterly, 2024-12-31) — Working Capital: -319605.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 909279.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 343086.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 22927060.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 2203346.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Capital Stock: 45935.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 226727.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 226727.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Common Stock: 45935.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: -500147.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Current Assets: 569813.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 413515.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 413515.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 1322794.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Derivative Product Liabilities: 535046.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 182025.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Gross PPE: 2192649.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Invested Capital: -500147.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 1789831.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 1789831.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Minority Interest: -46264.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Net PPE: 2192649.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -682172.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Non Current Prepaid Assets: 156773.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 4593539.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Other Equity Interest: 13983115.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Other Properties: 2192649.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Payables: 909279.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -34428086.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Share Issued: 4593539.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: -500147.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -682172.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Assets: 3101260.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Capitalization: -500147.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Debt: 2203346.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: -546411.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 3647671.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 2531447.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2324877.00
HEMO.L balance_sheet (quarterly, 2025-06-30) — Working Capital: -752981.00
HEMO.L income_statement (annual, 2025-12-31) — +Operating Expense: 3730999.00
HEMO.L income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
HEMO.L balance_sheet (annual, 2025-12-31) — Accounts Payable: 965148.00
HEMO.L balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 965148.00
HEMO.L balance_sheet (annual, 2025-12-31) — Accounts Receivable: 8776.00
HEMO.L balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 8776.00
HEMO.L balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -799381.00
HEMO.L balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -799381.00
HEMO.L balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 29239910.00
HEMO.L balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 29239910.00
HEMO.L income_statement (annual, 2025-12-31) — Basic Average Shares: 4442691.00
HEMO.L income_statement (annual, 2025-12-31) — Basic EPS: -1.71
HEMO.L cash_flow (annual, 2025-12-31) — Beginning Cash Position: 159265.00
HEMO.L balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 636269.00